Cell therapy · Kills target cells · developed by Immatics US
IMA203CD8 is a cell therapy made of autologous T cells selected as CD3+CD8+ HLA-Dextramer+ cells, dosed by body surface area. It is studied in adult patients with refractory or recurrent solid tumors and other cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03686124 | Phase 1/2 | Refractory Cancer | Recruiting | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerRecurrent CancerRefractory CancerSolid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →